BCLI Brainstorm Cell Therapeutics Inc

Price (delayed)

$0.532

Market cap

$36.36M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.4

Enterprise value

$36.33M

BrainStorm Cell Therapeutics Inc. is a leading developer of innovative autologous adult stem cell therapeutics for debilitating neurodegenerative diseases. The Company holds the rights to clinical development and commercialization of ...

Highlights

BCLI's debt has plunged by 69% YoY and by 56% from the previous quarter

The EPS has increased by 39% year-on-year and by 7% since the previous quarter

The net income has increased by 29% YoY but it has decreased by 3.4% QoQ

The equity has plunged by 88% from the previous quarter and by 61% YoY

BCLI's quick ratio has shrunk by 51% YoY and by 26% QoQ

Sector: Healthcare

Industry: Biotechnology

Website: http://www.brainstorm-cell.com

Peers: GILD CYTK AGEN BIIB

Key stats

What are the main financial stats of BCLI

Market

Shares outstanding

68.34M

Market cap

$36.36M

Enterprise value

$36.33M

Valuations

Price to earnings (P/E)

N/A

Price to book (P/B)

N/A

Price to sales (P/S)

N/A

EV/EBIT

N/A

EV/EBITDA

N/A

EV/Sales

N/A

Earnings

Revenue

EBIT

-$16.75M

EBITDA

-$16.48M

Free cash flow

-$20.48M

Per share

EPS

-$0.4

Free cash flow per share

-$0.48

Book value per share

-$0.1

Revenue per share

TBVPS

$0.1

Balance sheet

Total assets

$4.21M

Total liabilities

$9.07M

Debt

$1.28M

Equity

-$4.86M

Working capital

-$5.9M

Liquidity

Debt to equity

-0.26

Current ratio

0.24

Quick ratio

0.17

Net debt/EBITDA

Margins

EBITDA margin

N/A

Gross margin

N/A

Net margin

N/A

Operating margin

N/A

Efficiency

Return on assets

-292.5%

Return on equity

N/A

Return on invested capital

N/A

Return on capital employed

N/A

Return on sales

N/A

Dividend

Dividend yield

N/A

DPS

N/A

Payout ratio

N/A

BCLI stock price

How has the Brainstorm Cell Therapeutics stock price performed over time

Intraday

-3.27%

1 week

4.31%

1 month

-18.78%

1 year

-80.86%

YTD

94.87%

QTD

-5.79%

Financial performance

How have Brainstorm Cell Therapeutics's revenue and profit performed over time

Revenue

Gross profit

Operating income

-$21.44M

Net income

-$17.19M

Gross margin

N/A

Net margin

N/A

The net income has increased by 29% YoY but it has decreased by 3.4% QoQ

Brainstorm Cell Therapeutics's operating income has increased by 14% YoY

Growth

What is Brainstorm Cell Therapeutics's growth rate over time

Valuation

What is Brainstorm Cell Therapeutics stock price valuation

P/E

N/A

P/B

N/A

P/S

N/A

EV/EBIT

N/A

EV/EBITDA

N/A

EV/Sales

N/A

The EPS has increased by 39% year-on-year and by 7% since the previous quarter

The equity has plunged by 88% from the previous quarter and by 61% YoY

Efficiency

How efficient is Brainstorm Cell Therapeutics business performance

The return on assets has dropped by 100% year-on-year and by 22% since the previous quarter

Dividends

What is BCLI's dividend

DPS

N/A

Dividend yield

N/A

Payout ratio

N/A

There are no recent dividends present for BCLI.

Financial health

How did Brainstorm Cell Therapeutics financials performed over time

Brainstorm Cell Therapeutics's total assets is 54% less than its total liabilities

BCLI's quick ratio has shrunk by 51% YoY and by 26% QoQ

Brainstorm Cell Therapeutics's total assets has plunged by 50% YoY and by 26% from the previous quarter

BCLI's debt is 126% more than its equity

The equity has plunged by 88% from the previous quarter and by 61% YoY

The company's debt to equity has surged by 81% YoY and by 77% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.